RESUMO
Paediatric radiotherapy differs greatly from its practice in adults mainly because of the age (median age 6 years), which poses the problem of irradiation of healthy tissues in a growing organism, causing sequelae, difficult compliance and management of parents. These particularities require a dedicated education and specific organisation that was set progressively concerning indications, quality control, exhaustive collection of native dosimetry, long-term follow-up and clinical and translational research, as well as accreditations to practice paediatric radiotherapy, in close collaboration with the French society of child and adolescent cancer and leukaemia (SFCE), under the aegis of the French group of paediatric radiotherapy (GFRP). This organization is a pioneer in the development of pediatric radiotherapy quality controls, which are becoming the European standard and in the collection of native dosimetry integrated with the follow-up of possible late-effects, constituting the most important international database.
Assuntos
Neoplasias , Radioterapia (Especialidade) , Adolescente , Adulto , Criança , Bases de Dados Factuais , França , Humanos , Oncologia , Neoplasias/radioterapiaRESUMO
A third of children with cancer receive radiotherapy as part of their initial treatment, which represents 800 paediatric irradiations per year in France carried out in 15 specialized centres approved on the recommendations of the French national cancer institute in decreasing order of frequency, the types of cancer that require irradiation are: brain tumours, neuroblastomas, Ewing's sarcomas, Hodgkin's lymphomas, soft tissue sarcomas including rhabdomyosarcomas, and nephroblastomas. The treatment guidelines follow the recommendations of the French society for childhood cancers (SFCE) or the French and European prospective protocols. The therapeutic indications, the technical and/and ballistic choices of complex cases are frequently discussed during bimonthly paediatric radiotherapy technical web-conferences. All cancers combined, overall survival being 80%, long-term toxicity logically becomes an important concern, making the preparation of treatments complex. The irradiation methods include all the techniques currently available: 3D conformational irradiation, intensity modulation radiation therapy, irradiation under normal or hypofractionated stereotaxic conditions, brachytherapy and proton therapy. We present the update of the recommendations of the French society for radiation oncology on the indications, the technical methods of realization and the organisation and the specificities of paediatric radiation oncology.
Assuntos
Neoplasias/radioterapia , Neoplasias Encefálicas/radioterapia , Institutos de Câncer , Neoplasias Cerebelares/radioterapia , Criança , Pré-Escolar , Radiação Cranioespinal/métodos , França , Doença de Hodgkin/radioterapia , Humanos , Neoplasias Renais/radioterapia , Meduloblastoma/radioterapia , Neuroblastoma/radioterapia , Radio-Oncologistas/educação , Radioterapia (Especialidade)/organização & administração , Radioterapia/métodos , Radioterapia/normas , Rabdomiossarcoma/radioterapia , Sarcoma de Ewing/radioterapia , Neoplasias de Tecidos Moles/radioterapia , Tumor de Wilms/radioterapiaRESUMO
Along with surgery, radiation therapy (RT) remains an essential option to cure patients suffering from medulloblastoma. However, its long-term adverse effects, particularly due to craniospinal irradiation (CSI), which is necessary to eradicate microscopic spread, are a limiting factor. The most frequent sequelae involve neurocognitive and endocrine impairment, which occurs in nearly all patients. Recent progress achieved through genetic and molecular biology offers the possibility to better stratify patients according to risk factors such as age, post-resection tumour residue and metastasis. Thus, new therapeutic studies assess the possibility to reduce radiation dose and/or radiation field size for patients with the most favourable prognosis. New radiotherapy techniques are also used such as Intensity-Modulated Radiotherapy (IMRT), tomotherapy and proton therapy, which aim at reducing the dose delivered to normal tissue. Conventional photon-based therapy has a relatively high exit dose in contrast with proton therapy which causes less damage to surrounding healthy tissue. It is noteworthy that each technique requires a long follow-up in order to prove that late effects could be reduced without compromising survival rates. Dosimetric comparison theoretically suggests that proton therapy may be the superior method for CSI in terms of late effects, but further research is needed to firmly establish this. Whatever the technique used, the great complexity of CSI requires discipline and expertise along with an external quality control online before the first RT session.
Assuntos
Neoplasias Cerebelares/radioterapia , Radiação Cranioespinal/efeitos adversos , Meduloblastoma/radioterapia , Ototoxicidade/etiologia , Terapia com Prótons , Neoplasias Cerebelares/diagnóstico , Neoplasias Cerebelares/cirurgia , Criança , Radiação Cranioespinal/tendências , Feminino , Humanos , Masculino , Meduloblastoma/diagnóstico , Meduloblastoma/cirurgia , Ototoxicidade/diagnóstico , Prognóstico , Terapia com Prótons/tendências , Fatores de RiscoRESUMO
Split-thickness skin autografts (AGs) are the standard surgical treatment for severe burn injuries. However, the treatment of patients with substantial skin loss is limited by the availability of donor sites for skin harvesting. As an alternative to skin autografts, our research group developed autologous self-assembled skin substitutes (SASSs), allowing the replacement of both dermis and epidermis in a single surgical procedure. The aim of the study was to assess the clinical outcome of the SASSs as a permanent coverage for full-thickness burn wounds. Patients were recruited through the Health Canada's Special Access Program. SASSs were grafted on debrided full-thickness wounds according to similar protocols used for AGs. The graft-take and the persistence of the SASS epithelium over time were evaluated. 14 patients received surgical care with SASSs. The mean percentage of the SASS graft-take was 98 % (standard deviation = 5) at 5 to 7 d after surgery. SASS integrity persisted over time (average follow-up time: 3.2 years), without noticeable deficiency in epidermal regeneration. Assessment of scar quality (skin elasticity, erythema, thickness) was performed on a subset of patients. Non-homogeneous pigmentation was noticed in several patients. These results indicated that the SASS allowed the successful coverage of full-thickness burns given its high graft-take, aesthetic outcome equivalent to autografting and the promotion of long-term tissue regeneration. When skin donor sites are in short supply, SASSs could be a valuable alternative to treat patients with full-thickness burns covering more than 50 % of their total body surface area.
Assuntos
Queimaduras/terapia , Transplante de Pele , Pele Artificial , Adulto , Queimaduras/patologia , Sobrevivência Celular , Elasticidade , Células Epiteliais/patologia , Feminino , Humanos , Estimativa de Kaplan-Meier , Masculino , Transplante Autólogo , Resultado do TratamentoRESUMO
PURPOSE: The only prognostic factor of prostate-specific antigen (PSA) bounce in prostate cancer found in several studies is young age but has never been specifically studied in this subset of patients for long-term results. Bounce characteristics, histological, clinical, and dosimetric data in young patients were analyzed, as well as their impact on toxicity and survival. MATERIAL AND METHODS: This retrospective study included patients aged ≤60 years treated with exclusive iodine 125 brachytherapy with low or intermediary prostate adenocarcinoma during 1999-2014. Exclusion criteria were a follow-up of ≤24 months. PSA bounce was defined as a ≥0.2-ng/mL increase above the interval PSA nadir, followed by a decrease to nadir or below. RESULTS: This study analyzed 179 patients. Median age was 56 years (46-59 years). The median follow-up was 79 months (54; 123). The bounce incidence was 56.8% (49.6%; 64.2%) at 5 years, inversely proportional to positive/total biopsies ratio (HR 0.98, 95% CI [0.97, 0.99]). Incidence of biochemical failure was 1.2%, 95% CI (0.3%; 4.7%), at 5 years with no difference between the bounce and no-bounce group (HR 0.96, 95% CI [0.25; 3.58]). Bounce is an unfavorable prognostic factor for grade two and three urinary toxicities 6.67 (4.14; 10.76) (p < 0.001). CONCLUSIONS: PSA bounce is common in young people after brachytherapy. It should be monitored without starting an inadequate and sometimes invasive relapse checkup or a relapse treatment.
Assuntos
Adenocarcinoma/radioterapia , Braquiterapia/efeitos adversos , Antígeno Prostático Específico/análise , Neoplasias da Próstata/radioterapia , Adenocarcinoma/sangue , Adenocarcinoma/mortalidade , Fatores Etários , Braquiterapia/métodos , Seguimentos , Humanos , Incidência , Radioisótopos do Iodo/administração & dosagem , Radioisótopos do Iodo/efeitos adversos , Masculino , Pessoa de Meia-Idade , Recidiva Local de Neoplasia/epidemiologia , Prognóstico , Neoplasias da Próstata/sangue , Neoplasias da Próstata/mortalidade , Estudos Retrospectivos , Análise de Sobrevida , Falha de TratamentoRESUMO
PURPOSE: Irradiation (>3Gy) to the breast or axillae before 30years of age increases the risk of secondary breast cancer (SBC). The purpose of this article is to describe the clinical characteristics of SBC and the way of diagnosis in young women (before the age of national screening) in France who had received previous radiotherapy for a childhood or a young adulthood cancer. PATIENTS AND METHODS: This retrospective, multicentre study reviewed the medical records of women with SBC before the age of the national screening who had received irradiation (≥3Gy) on part or all of the breast before 30years of age, for any type of tumour except BC. RESULTS: A total of 121 SBC were detected in 104 women with previous radiotherapy. Twenty percent of SBC were detected during regular breast screening and 16% of the women had a regular radiological follow-up. CONCLUSION: Our results points out that the main proportion of childhood cancer survivors did not benefit from the recommended breast cancer screening. This result is comparable to other previously published studies in other countries. A national screening programme is necessary and should take into account the patient's age, family history, personal medical history and previous radiotherapy to reduce the number of SBC diagnosed at an advanced stage.
Assuntos
Neoplasias da Mama/diagnóstico , Neoplasias da Mama/etiologia , Neoplasias Induzidas por Radiação/diagnóstico , Segunda Neoplasia Primária/diagnóstico , Neoplasias/radioterapia , Adulto , Mama/efeitos da radiação , Neoplasias da Mama/patologia , Detecção Precoce de Câncer , Feminino , França , Humanos , Glândulas Mamárias Humanas/efeitos da radiação , Mamografia , Pessoa de Meia-Idade , Neoplasias Induzidas por Radiação/etiologia , Neoplasias Induzidas por Radiação/patologia , Segunda Neoplasia Primária/etiologia , Segunda Neoplasia Primária/patologia , Radioterapia/efeitos adversos , Estudos Retrospectivos , Sobreviventes , Adulto JovemRESUMO
PURPOSE: To study overall survival, risk of neurological death, local recurrence and development of new brain metastasis in patients treated for brain oligometastases with hypofractionated stereotactic radiotherapy with CyberKnife®, according to the association or not with an additional whole brain irradiation. PATIENTS AND METHODS: Institutional retrospective study of 102 patients treated for one to three brain metastasis: 76 with exclusive hypofractionated stereotactic radiotherapy and 26 with hypofractionated stereotactic radiotherapy and whole brain irradiation. Objectives were assessed and compared between these two groups according to the Kaplan-Meier method and Cox model. RESULTS: Median follow-up was 18.8 months. There were no difference between exclusive hypofractionated stereotactic radiotherapy and hypofractionated stereotactic radiotherapy with whole brain irradiation for overall survival (respective median 21.5 and 20.1 months), risk of neurological death (respectively 9.2% and 15.4% at one year). At one year: the risk of cerebral progressive disease was greater in the group receiving exclusive hypofractionated stereotactic radiotherapy (respectively 43.4% vs. 26.2%, P=0.043), the risk of local recurrence was 25% versus 17.6% (P=0.28) and the development of new brain metastasis was 23.7% versus 11.5% (P=0.27). After salvage treatments, crude local control was similar in the two groups, respectively 78.6% and 73.5%. Whole brain irradiation has been avoided for 72.4% of patients in the group receving exclusive hypofractionated stereotactic radiotherapy. CONCLUSION: Whole brain irradiation improves local control of brain metastatic disease in addition to hypofractionated stereotactic radiotherapy. Sparing whole brain irradiation for salvage treatments only does not affect overall survival or risk of neurological death in selected patients with favourable prognosis.
Assuntos
Neoplasias Encefálicas/radioterapia , Neoplasias Encefálicas/secundário , Hipofracionamento da Dose de Radiação , Radiocirurgia/métodos , Adulto , Idoso , Idoso de 80 Anos ou mais , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Estudos RetrospectivosRESUMO
Neonatal herpes simplex virus infection is rare but important to recognize because of the major risk of sequelae or death. The diagnosis is mainly based on specific clinical and biological analyses. Aciclovir is the treatment of choice, duration of administration depending on the severity of the disease. A six-month treatment with suppressive-dose oral aciclovir is recommended to improve the child's prognosis. From a clinical case, we reviewed the literature to improve the management.
L'infection néonatale à Herpès est peu fréquente mais importante à reconnaître vu le risque important de séquelles ou de mortalité. Le diagnostic repose principalement sur des analyses cliniques et biologiques spécifiques. L'aciclovir est le traitement de choix, la durée d'administration varie en fonction de l'importance de l'atteinte. Un traitement de 6 mois par voie orale est conseillé pour améliorer le pronostic de l'enfant. A partir d'un cas clinique, nous avons revu la littérature pour connaître les dernières recommandations afin d'améliorer la prise en charge.
Assuntos
Aciclovir/uso terapêutico , Combinação Amoxicilina e Clavulanato de Potássio/uso terapêutico , Antivirais/uso terapêutico , Herpes Simples/tratamento farmacológico , Complicações Infecciosas na Gravidez/tratamento farmacológico , Inibidores de beta-Lactamases/uso terapêutico , Feminino , Herpes Simples/diagnóstico , Humanos , Recém-Nascido , Complicações Infecciosas na Gravidez/diagnósticoRESUMO
The purpose of this article is to describe the specificities of paediatric radiation oncology: cancer types, radiotherapy indications, techniques, organisation and reglementary framework.
Assuntos
Neoplasias/radioterapia , Adolescente , Institutos de Câncer , Quimiorradioterapia , Criança , Pré-Escolar , Terapia Combinada , Irradiação Craniana/efeitos adversos , Irradiação Craniana/métodos , Irradiação Craniana/normas , Fracionamento da Dose de Radiação , França , Humanos , Lactente , Recém-Nascido , Neoplasias/terapia , Órgãos em Risco , Pediatria/organização & administração , Lesões por Radiação/prevenção & controle , Radioterapia (Especialidade)/organização & administração , Radiocirurgia/efeitos adversos , Radiocirurgia/métodos , Radiocirurgia/normas , Radioterapia/efeitos adversos , Radioterapia/métodos , Radioterapia/normas , Dosagem Radioterapêutica , Planejamento da Radioterapia Assistida por Computador , Sociedades MédicasRESUMO
PURPOSE: Radiotherapy is a rare indication in paediatric oncology, with 800 to 900 children in treatment per year in France. Child cancers represent approximately 1% of cancers in France and half occur before the age of 5 years. Paediatric radiation requires appropriate tools, local, time and specific training. In France, in 2015, 18 centres are accredited by the French National Cancer Institute (INCa) for this activity. MATERIAL AND METHODS: Survey conducted in February 2015 on the care of children (0 to 18 years) in radiotherapy departments in France. The survey was sent to the radiation oncologists involved in the 18 centres. The questions concerned the qualitative and quantitative aspect, medical and organizational aspects, and the involvement of assistant practitioners in the management of this activity. RESULTS: Seventeen centres responded. In 2014, 889 children under 18 were treated in radiotherapy departments. These departments are working together with one to four paediatric oncology departments. Regarding access to general anaesthesia: three centres perform one to seven treatment(s) under anaesthesia per year, three centres eight to ten treatments under anaesthesia per year, three centres ten to 24 treatments under anaesthesia per year and nine centres out of 17 use hypnosis techniques. In terms of human resources, in 2015, 29 radiation therapists have a paediatric radiotherapy activity. Involvement of assistant practitioners is growing and specific training are desired. Regarding treatment preparation and delivery, 13 centres have specific paediatric contentions, 14 of 16 centres employ radiation intensity modulated if dosimetry is more satisfying with 11 regularly to the craniospinal irradiation. Radiotherapy on moving areas with respiratory gating or hypofractionation is under developed. CONCLUSION: Paediatric radiation therapy is a specific activity requiring a dedicated management, both in human, organizational, medical and scientific aspects.
Assuntos
Pediatria , Padrões de Prática Médica/estatística & dados numéricos , Radioterapia/métodos , Radioterapia/estatística & dados numéricos , Pessoal Técnico de Saúde/estatística & dados numéricos , Anestesia Geral/estatística & dados numéricos , Criança , França , Humanos , Neoplasias/radioterapia , Sociedades Médicas , Inquéritos e Questionários , Tecnologia Radiológica , Recursos HumanosRESUMO
A survey was conducted in 2015 in France on the care of children in radiotherapy services. We present the results for total body irradiation in children, a specific technique of radiation treatment, which needs dedicated controls for this particular population. Of the 17 centres interviewed, 16 responded, and 13 practiced total body irradiation. Patients are positioned in lateral decubitus in 11 centres and supine/prone in two centres. Doses used for total body irradiation in myeloablative bone marrow transplantation are the same in all centres (12Gy); treatments are always fractionated. Lung shielding is positioned to limit the dose at an average of 8Gy with extremes ranging from 6 to 10Gy. The shape of the shieldings varies depending on departments' protocol, with a smaller size in case of mediastinal mass. Four centres have experience of total body irradiation under general anaesthesia, despite twice-daily fractions. In total, practice is relatively homogeneous throughout France and is inspired by the knowledge obtained in adults.
Assuntos
Padrões de Prática Médica/estatística & dados numéricos , Irradiação Corporal Total/estatística & dados numéricos , Anestesia Geral/estatística & dados numéricos , Criança , França , Humanos , Órgãos em Risco , Posicionamento do Paciente/estatística & dados numéricos , Proteção Radiológica/estatística & dados numéricos , Dosagem Radioterapêutica , Inquéritos e QuestionáriosRESUMO
PURPOSE: To evaluate the maximum tolerated dose of simultaneous integrated-boost intensity-modulated radiotherapy (SIB-IMRT) associated with temozolomide in patients with glioblastoma. PATIENTS AND METHODS: Between November 2009 and January 2012, nine patients with malignant glioma were enrolled in this phase I clinical trial. Radiotherapy was delivered using fractions of 2.5Gy on the planning target volume b and of 1.9Gy on the planning target volume a. Volumes were defined as follow: gross tumour volume b: tumour taking up contrast on T1 weighted MRI images; clinical target volume b: gross tumour volume b+0.5cm (adapted to the anatomical structures) and lastly planning target volume b: clinical target volume b+0.5cm; gross tumour volume a: tumour (gross tumour volume b)+2cm and including oedema outlined on T2Flair MRI sequences; clinical target volume a gross tumour volume a+0.5cm (adapted to the anatomical structures); planning target volume a: clinical target volume a+0.5cm. Three patients were enrolled at each of the three levels of dose (70, 75 and 80Gy prescribed on the planning target volume b and 56, 60 and 60.8Gy on the planning target volume a). Radiotherapy was delivered with temozolomide according to the standard protocol. Dose-limiting toxicities were defined as any haematological toxicities at least grade 4 or as any radiotherapy-related non-haematological acute toxicities at least grade 3, according to the Common Terminology Criteria for Adverse Events, version 3.0. RESULTS: Until the last dose level of 80Gy, no patient showed dose-limiting toxicity. CONCLUSIONS: SIB-IMRT, at least until a dose of 80Gy in 32 daily fractions, associated with temozolomide is feasible and well tolerated.
Assuntos
Antineoplásicos Alquilantes/administração & dosagem , Neoplasias Encefálicas/tratamento farmacológico , Neoplasias Encefálicas/radioterapia , Dacarbazina/análogos & derivados , Glioblastoma/tratamento farmacológico , Glioblastoma/radioterapia , Radioterapia de Intensidade Modulada , Adulto , Idoso , Antineoplásicos Alquilantes/efeitos adversos , Terapia Combinada , Dacarbazina/administração & dosagem , Dacarbazina/efeitos adversos , Feminino , Humanos , Masculino , Dose Máxima Tolerável , Pessoa de Meia-Idade , Dosagem Radioterapêutica , TemozolomidaRESUMO
We report on a phase II clinical trial to determine the effect of a concurrent ultra-fractionated radiotherapy and temozolomide treatment in inoperable glioblastoma patients. A phase II study opened; patients over 18 years of age who were able to give informed consent and had histologically proven, newly diagnosed inoperable diagnosed and supratentorial glioblastoma were eligible. Three doses of 0.75 Gy spaced apart by at least 4 hr were delivered daily, 5 days a week for six consecutive weeks for a total of 67.5 Gy. Chemotherapy was administered during the same period, which consisted of temozolomide given at a dose of 75 mg/m(2) for 7 days a week. After a 4-week break, chemotherapy was resumed for up to six cycles of adjuvant temozolomide treatment, given every 28 days, according to the standard 5-day regimen. Tolerance and toxicity were the primary endpoints; survival and progression-free survival were the secondary endpoints. In total, 40 patients were enrolled in this study, 29 men and 11 women. The median age was 58 years, and the median Karnofsky performance status was 80. The concomitant ultra-fractionated radiotherapy and temozolomide treatment was well tolerated. Complete responses were seen in four patients, and partial responses were reported in seven patients. The median survival from the initial diagnosis was 16 months. Several long-term survivors were noted. Concurrent ultra-fractionated radiation therapy and temozolomide treatment are well accepted by the patients. The results showed encouraging survival rates for these unfavorable patients.
Assuntos
Antineoplásicos Alquilantes/uso terapêutico , Neoplasias Encefálicas/patologia , Neoplasias Encefálicas/terapia , Dacarbazina/análogos & derivados , Glioblastoma/patologia , Glioblastoma/terapia , Radioterapia de Intensidade Modulada/métodos , Adulto , Idoso , Antineoplásicos Alquilantes/administração & dosagem , Antineoplásicos Alquilantes/efeitos adversos , Neoplasias Encefálicas/mortalidade , Quimiorradioterapia , Metilação de DNA , Metilases de Modificação do DNA/genética , Enzimas Reparadoras do DNA/genética , Dacarbazina/administração & dosagem , Dacarbazina/efeitos adversos , Dacarbazina/uso terapêutico , Feminino , França , Glioblastoma/mortalidade , Humanos , Masculino , Pessoa de Meia-Idade , Radioterapia de Intensidade Modulada/efeitos adversos , Temozolomida , Resultado do Tratamento , Carga Tumoral , Proteínas Supressoras de Tumor/genéticaRESUMO
Whole brain radiation therapy is the angular stone of the brain metastasis radiation therapy. This treatment allows reaching two goals, potentially curative for in place metastasis and prophylactic in the rest of brain tissue. However, these two advantages can be disputed and in light of the same data opposite conclusions could be drawn.
Assuntos
Neoplasias Encefálicas/secundário , Irradiação Craniana , Corticosteroides/uso terapêutico , Alopecia/etiologia , Encéfalo/patologia , Encéfalo/efeitos da radiação , Neoplasias Encefálicas/tratamento farmacológico , Neoplasias Encefálicas/prevenção & controle , Neoplasias Encefálicas/radioterapia , Terapia Combinada , Irradiação Craniana/efeitos adversos , Irradiação Craniana/métodos , Humanos , Transtornos da Memória/etiologia , Estudos Multicêntricos como Assunto , Necrose , Recidiva Local de Neoplasia/radioterapia , Estudos Prospectivos , Lesões por Radiação/etiologia , Radiossensibilizantes/uso terapêutico , Análise de Sobrevida , Resultado do TratamentoRESUMO
PURPOSE: Due to the extensive initial distant tumour spread in metastatic rhabdomyosarcoma, the importance of local treatment is sometimes underestimated. A retrospective study was conducted to identify the prognostic value of aggressive local treatment in paediatric metastatic rhabdomyosarcoma. PATIENTS: Patients with metastatic rhabdomyosarcoma aged 1-21 years treated in France from 1998 to 2011 according to European protocols MMT-4-89, 4-91, 98 and recent national guidelines were selected. Survival comparison were performed between patients with 'aggressive local treatment' (surgery and radiotherapy) and exclusive surgery or radiotherapy, after exclusion of patients with early progression. End-points were event-free and overall survival (OS). RESULTS: A total of 101 children, median age 9 years, with majority of primaries in unfavourable sites (73 patients, pts), T2 tumours (66 pts), alveolar subtypes (65 pts) and large tumours (>5 cm, 83 pts) received various chemotherapy regimens. On univariate and multivariate analyses, OS was better after 'aggressive local treatment' (49 pts; 44.3 ± 8%), than after exclusive surgery (10 pts; 18.8% ± 15.5%) or exclusive radiotherapy (29 pts; 16.1 ± 7.2%, P < 0.006). Moreover, OS was better in the case of surgery with complete resection (41.1 ± 10.2%) or microscopic residue (56.4 ± 14.9%) than macroscopic residue (20.0 ± 12.6%; P < 0.03). CONCLUSIONS: In this large retrospective analysis, OS appeared to be better for patients receiving 'aggressive local treatment' even after adjustment for the initial patient and tumour characteristics. Isolated debulking surgery is associated with a very poor outcome and should be avoided. Aggressive local treatment in patients with rhabdomyosarcoma, even with metastasis, should be seriously considered.
Assuntos
Rabdomiossarcoma/cirurgia , Rabdomiossarcoma/terapia , Adolescente , Quimiorradioterapia , Criança , Pré-Escolar , Terapia Combinada , Feminino , Humanos , Lactente , Estimativa de Kaplan-Meier , Masculino , Análise Multivariada , Metástase Neoplásica , Prognóstico , Estudos Retrospectivos , Rabdomiossarcoma/patologia , Resultado do Tratamento , Adulto JovemRESUMO
PURPOSE: To compare several techniques in order to determine the best treatment for benign brain tumours. METHODS AND PATIENTS: A retrospective study was performed for five patients who received 3D-conformal radiotherapy, intensity modulated radiotherapy or CyberKnife(®). These patients had a meningioma, a pituitary tumour, a craniopharyngioma or a neurinoma. In each case, these treatment plans were optimised and compared with the three other dosimetries. Radiobiological or positioning parameters were evaluated, as well as dosimetric parameters, in order to compare treatments with different characteristics. RESULTS: The dosimetric parameters showed that the choice of treatment seemed to be determined mostly by tumour size, shape and proximity with organs at risk (not tumour localisation). Whereas the results showed no significant deviations with regards to the radiobiological parameters. Therefore, with these parameters, it was difficult to give priority to a treatment. CONCLUSIONS: With regards to benign brain tumours of medium or large size, intensity modulated radiotherapy seemed the recommended treatment. It enabled to obtain a good ratio between efficacy and toxicity for tumours that are really close to organs at risk. Concerning small benign brain tumours, the CyberKnife(®) was probably the best treatment.
Assuntos
Neoplasias Encefálicas/radioterapia , Radioterapia Conformacional/métodos , Radioterapia de Intensidade Modulada/métodos , Robótica , Técnicas Estereotáxicas , Criança , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Dosagem Radioterapêutica , Planejamento da Radioterapia Assistida por Computador , Estudos RetrospectivosRESUMO
INTRODUCTION: The term of "medulloblastoma" refers to cerebellar tumors belonging to the family of primitive neuro-ectodermic tumors (PNET). Medulloblastomas represent 40% of cerebellar tumors, 15 to 20% of brain tumors and the first cause of malignant brain tumors in childhood. Seventy to 80% of cases are diagnosed in children versus 20 to 30% in adults. UPDATED KNOWLEDGE: Diagnosis is based on clinical and radiological exams, and proved on pathological analysis in association with molecular biology. Treatment comprises surgery, craniospinal radiotherapy except for children under five years of age and chemotherapy according to age and high-risk criteria. Medulloblastoma is a rare case of a central nervous system tumor which is radio- and chemo-sensitive. Treatment goals are, on one hand, to improve the survival rates and, on the other hand, to avoid late neurocognitive, neuroendocrine and orthopedic side effects related to radiation therapy, notably in children. The prognosis is relatively good, with a five year survival rate over 75% after complete resection of a localized tumor although sequelae may still compromise outcome. PERSPECTIVES AND CONCLUSION: Management of patients with medulloblastoma implies a multidisciplinary approach combining the contributions of neurosurgery, neuroradiology, pediatric oncology, neuro-oncology and radiotherapy teams.
Assuntos
Neoplasias Cerebelares , Meduloblastoma , Neoplasias Cerebelares/diagnóstico , Neoplasias Cerebelares/terapia , Humanos , Meduloblastoma/diagnóstico , Meduloblastoma/terapia , Resultado do TratamentoAssuntos
Infertilidade Feminina/etiologia , Neoplasias/radioterapia , Ovário/efeitos da radiação , Lesões por Radiação/etiologia , Útero/efeitos da radiação , Adulto , Quimioterapia Adjuvante , Criança , Terapia Combinada , Feminino , Seguimentos , Humanos , Sistema Hipotálamo-Hipofisário/efeitos dos fármacos , Sistema Hipotálamo-Hipofisário/efeitos da radiação , Infertilidade Feminina/induzido quimicamente , Neoplasias/tratamento farmacológico , Ovário/efeitos dos fármacos , Gravidez , Complicações na Gravidez/etiologia , Dosagem Radioterapêutica , Útero/efeitos dos fármacosRESUMO
Stereotactic radiotherapy delivers allows for a highly precise irradiation, and was originally developed in the 70s by neurosurgeons. Gradually, it has been developed in extracranial indications. Moreover new innovative treatment devices such as the robotic radiosurgery with CyberKnife have emerged. Indications are currently being validated by the HAS in intracranial locations that are treated by conventional radiosurgery for several decades. Three robotic radiosurgery facilities were opened in France in 2006 thanks to a grant from the INCa. Those are posed in Lille, Nice, Nancy. Since 2007, 140 patients were treated as off today in Alexis Vautrin Cancer Center (40 intracranial locations, 100 extracranial). Thirty five primitive lung cancer or pulmonary metastasis, twenty primary liver tumor or metastasis, 21 spinal locations (schwanomas or bone metastasis), and nineteen other (pelvic lymph nodes, chordomas, H&N, etc.). The lung diseases were treated on the 80% isodose as follow: 60 Gy in three fractions for peripheral tumors and 54 Gy for central ones. The one-year local control rate reaches 90%. The hepatic tumors received 45 Gy in three fractions prescribed on the 80% isodose with a six months local control rate of 83%. Any of the 140 patients has suffered from acute or late toxicity > grade 3. These encouraging outcomes are confirmed by both other French centers and phase II trial are pending to assess the most effective and safe radiations protocols.